Analytical and bioanalytical technologies for characterizing antibody-drug conjugates

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 406-411

  Alley, Stephen C ^a   Anderson, Kevin E ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; AURISTATIN; CALICHEAMICIN; DRUG ANTIBODY; MAYTANSINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIGEN BINDING; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PEPTIDE MAPPING; PHYSICAL CHEMISTRY; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY TECHNIQUES, ANALYTICAL; HUMANS; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS;

EID: 84878857691     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.03.022     Document Type: Review

References (31)

1. Alley S.C., Okeley N.M., Senter P.D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010, 14:529-537.
2. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008, 41:98-107.
3. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932.
4. McDonagh C.F., Turcott E., Westendorf L., Webster J.B., Alley S.C., Kim K., Andreyka J., Stone I., Hamblett K.J., Francisco J.A., et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006, 19:299-307.
5. Axup J.Y., Bajjuri K.M., Ritland M., Hutchins B.M., Kim C.H., Kazane S.A., Halder R., Forsyth J.S., Santidrian A.F., Stafin K., et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A 2012, 109:16101-16106.
6. Hofer T., Skeffington L.R., Chapman C.M., Rader C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 2009, 48:12047-12057.
7. Wakankar A., Chen Y., Gokarn Y., Jacobson F.S. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011, 3:161-172.
8. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., Kissler K.M., Bernhardt S.X., Kopcha A.K., Zabinski R.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070.
9. Sanderson R.J., Hering M.A., James S.F., Sun M.M., Doronina S.O., Siadak A.W., Senter P.D., Wahl A.F. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005, 11:843-852.
10. Junutula J.R., Flagella K.M., Graham R.A., Parsons K.L., Ha E., Raab H., Bhakta S., Nguyen T., Dugger D.L., Li G., et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010, 16:4769-4778.
11. Lazar A.C., Wang L., Blattler W.A., Amphlett G., Lambert J.M., Zhang W. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom 2005, 19:1806-1814.
12. Wang L., Amphlett G., Blattler W.A., Lambert J.M., Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005, 14:2436-2446.
13. Shen B.Q., Xu K., Liu L., Raab H., Bhakta S., Kenrick M., Parsons-Reponte K.L., Tien J., Yu S.F., Mai E., et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012, 30:184-189.
14. Xu K., Liu L., Saad O.M., Baudys J., Williams L., Leipold D., Shen B., Raab H., Junutula J.R., Kim A., et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 2011, 412:56-66.
15. Valliere-Douglass J.F., McFee W.A., Salas-Solano O. Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Anal Chem 2012, 84:2843-2849.
16. Sun M.M., Beam K.S., Cerveny C.G., Hamblett K.J., Blackmore R.S., Torgov M.Y., Handley F.G., Ihle N.C., Senter P.D., Alley S.C. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005, 16:1282-1290.
17. Girish S., Gupta M., Wang B., Lu D., Krop I.E., Vogel C.L., Burris Iii H.A., LoRusso P.M., Yi J.H., Saad O., et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012, 69:1229-1240.
18. Alley S.C., Zhang X., Okeley N.M., Anderson M., Law C.L., Senter P.D., Benjamin D.R. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 2009, 330:932-938.
19. Erickson H.K., Lewis Phillips G.D., Leipold D.D., Provenzano C.A., Mai E., Johnson H.A., Gunter B., Audette C.A., Gupta M., Pinkas J., et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012, 11:1133-1142.
20. Shen B.Q., Bumbaca D., Saad O., Yue Q., Pastuskovas C.V., Khojasteh S.C., Tibbitts J., Kaur S., Wang B., Chu Y.W., et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012, 13:901-910.
21. Alley S.C., Benjamin D.R., Jeffrey S.C., Okeley N.M., Meyer D.L., Sanderson R.J., Senter P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008, 19:759-765.
22. Kaur S., Xu K., Saad O.M., Dere R.C., Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013, 5:201-226.
23. Stephan J.P., Kozak K.R., Wong W.L.T. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 2011, 3:677-700.
24. Boghaert E.R., Khandke K.M., Sridharan L., Dougher M., DiJoseph J.F., Kunz A., Hamann P.R., Moran J., Chaudhary I., Damle N.K. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother Pharmacol 2008, 61:1027-1035.
25. Tolcher A.W., Ochoa L., Hammond L.A., Patnaik A., Edwards T., Takimoto C., Smith L., de Bono J., Schwartz G., Mays T., et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003, 21:211-222.
26. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., Tan-Chiu E., Krop I.E., Michaelson R.A., Girish S., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29:398-405.
27. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
28. Younes A., Kim S., Romaguera J., Copeland A., Farial S.D.C., Kwak L.W., Fayad L., Hagemeister F., Fanale M., Neelapu S., et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012, 30:2776-2782.
29. Bender B.C., Schaedeli-Stark F., Koch R., Joshi A., Chu Y.W., Rugo H., Krop I.E., Girish S., Friberg L.E., Gupta M. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012, 70:591-601.
30. Gupta M., Lorusso P.M., Wang B., Yi J.H., Burris H.A., Beeram M., Modi S., Chu Y.W., Agresta S., Klencke B., et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 2012, 52:691-703.
31. Chudasama V.L., Schaedeli Stark F., Harrold J.M., Tibbitts J., Girish S.R., Gupta M., Frey N., Mager D.E. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 2012, 92:520-527.